Loading patent…
AssigneeKorea University Research and Business Foundation
InventorsCheol-Sang HWANG, Sang-Hyeon MUN
Estimating the term…
The present disclosure relates to a POMC-specific antibody and use thereof, and use of Marchf6 for treating metabolic diseases. It has been found that the cytosolic accumulation of POMC, which is an appetite-regulating hormone precursor protein, induces ER stress and ferroptosis, and Marchf6 degrades POMC by directly binding thereto, causing the translocation of POMC into ER. Also, it has been confirmed that a produced POMC-specific antibody can specifically detect POMC accumulated in the cytosol of POMC neurons. Therefore, these can be used for the diagnosis and treatment of diseases associated with POMC accumulation or Marchf6 dysfunction. It has also been found that ER stress and ferroptosis caused by accumulation of POMC in the cytosol are regulated. In particular, it was confirmed in vivo that Marchf6 deficiency in POMC neurons causes metabolic disorders. Therefore, Marchf6 can be effectively used for the prevention or treatment of metabolic diseases, including obesity.
An antigenic peptide for producing a pro-opiomelanocortin (POMC)-specific antibody, comprising an amino acid sequence represented by SEQ ID NO:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition for preventing or treating metabolic diseases, comprising a membrane associated ring-CH-type finger 6 (Marchf6) protein or fragment thereof, or an activator or expression promoter of Marchf6 as an active ingredient.
(canceled)
(canceled)
A composition for promoting degradation of pro-opiomelanocortin (POMC), comprising a Marchf6 protein or fragment thereof, or an activator or expression promoter of Marchf6.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.